Clinical Observation Of Paclitaxel Combined Oxaliplatin As First-line Treatment Of Advanced Gastric Cancer

Objective: To integrative the clinical efficacy of paclitaxel combined with oxaliplatinas first-line treatment in advanced gastric cancer, analyze the factors which affectedthe prognosis and the side effects of chemotherapy.Methods:105patients with thisdisease from Fujian Provincial Cancer Hospital (January2005to February2010) andFujian Medical University Union Hospital (March2010to March2013) received thetreatment of paclitaxel combined with oxaliplatin. The treatment cycle ranged from3cycles to12cycles. The factors which affected the efficacy, survival curves drew withKaplan-Meier method, clinical efficacy evaluated by RECIST1.1, relationshipbetween CEA and CA199and side effects evaluated by “CTCAE v4.0” were all usedto evaluate the effect of this treatment. Results: The OS of105cases was between2.5and29.1months, the median OS was14.8months and the median PFS was6.0months. There were12cases of CR,36cases of PR,43cases of SD and14cases ofPD. The DCR was86.7%and the RR was45.7%. Grouping analysis showed thatpatients who received palliative surgery or metastatic sites≤2had higher clinicalefficacy (P<0.05), and CA199was a significantly better indicator for clinical efficacy(P<0.05). Single factor analysis showed that patients who received palliative surgery,metastatic sites≤2and had good clinical efficacy had significantly better OS (P<0.05).The common grade1-2side effects included neurotoxicity, bone marrow depression,gastrointestinal reaction and liver and kidney function injury. Conclusion: Thetreatment of paclitaxel combined with oxaliplatin in advanced gastric cancer showedhigher RR and DCR and lower incidence of side effects. It is one of best treatments inadvanced gastric cancer.